OTCMKTS:PARD

Poniard Pharmaceuticals Competitors

$0.06
0.00 (0.00 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.03
$0.12
Volume37 shs
Average Volume6,258 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.35

Competitors

Poniard Pharmaceuticals (OTCMKTS:PARD) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying PARD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Poniard Pharmaceuticals, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and Poniard Pharmaceuticals (OTCMKTS:PARD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Acusphere and Poniard Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Poniard Pharmaceuticals0000N/A

Volatility & Risk

Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Poniard Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Earnings & Valuation

This table compares Acusphere and Poniard Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Acusphere and Poniard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/A

Summary

Poniard Pharmaceuticals beats Acusphere on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Poniard Pharmaceuticals (OTCMKTS:PARD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Earnings & Valuation

This table compares Affymax and Poniard Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Affymax and Poniard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/A

Volatility & Risk

Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Poniard Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Affymax and Poniard Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Poniard Pharmaceuticals0000N/A

Summary

Affymax beats Poniard Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Poniard Pharmaceuticals (OTCMKTS:PARD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares ARYx Therapeutics and Poniard Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares ARYx Therapeutics and Poniard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/A

Volatility and Risk

ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Comparatively, Poniard Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for ARYx Therapeutics and Poniard Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Poniard Pharmaceuticals0000N/A

Summary

Poniard Pharmaceuticals beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and Poniard Pharmaceuticals (OTCMKTS:PARD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for AtheroNova and Poniard Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
Poniard Pharmaceuticals0000N/A

Valuation & Earnings

This table compares AtheroNova and Poniard Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/AN/AN/A

Volatility and Risk

AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500. Comparatively, Poniard Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Profitability

This table compares AtheroNova and Poniard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
Poniard PharmaceuticalsN/AN/AN/A

Summary

Poniard Pharmaceuticals beats AtheroNova on 1 of the 1 factors compared between the two stocks.

Poniard Pharmaceuticals (OTCMKTS:PARD) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Poniard Pharmaceuticals and China Botanic Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poniard Pharmaceuticals0000N/A
China Botanic Pharmaceutical0000N/A

Earnings & Valuation

This table compares Poniard Pharmaceuticals and China Botanic Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poniard PharmaceuticalsN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Risk & Volatility

Poniard Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500.

Profitability

This table compares Poniard Pharmaceuticals and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poniard PharmaceuticalsN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

Summary

China Botanic Pharmaceutical beats Poniard Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Poniard Pharmaceuticals (OTCMKTS:PARD) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Poniard Pharmaceuticals and China Dongsheng International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poniard Pharmaceuticals0000N/A
China Dongsheng International0000N/A

Earnings & Valuation

This table compares Poniard Pharmaceuticals and China Dongsheng International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poniard PharmaceuticalsN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Risk & Volatility

Poniard Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500.

Profitability

This table compares Poniard Pharmaceuticals and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poniard PharmaceuticalsN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Summary

China Dongsheng International beats Poniard Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


Poniard Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$33.79flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.84flat$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.